SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Healthcare Value Capital, LLC

CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411

Reported Value
$30M
Q4 2020
Positions
17
Filings on Record
11
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Healthcare Value Capital, LLC reported $30M in U.S.-listed holdings across 17 positions for Q4 2020.

Its largest position, ABBV, represents 12.6% of the portfolio.

Compared with Q3 2020, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+16.3%
vs prior filed quarter
Top-10 Concentration
+81.1%
share of reported value
Largest Position
+12.6%
Abbvie
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $26MQ1 ’19Q2 ’19: $53MQ3 ’19: $55MQ3 ’19Q4 ’19: $34MQ1 ’20: $59MQ1 ’20Q2 ’20: $39MQ3 ’20: $30MQ3 ’20Q4 ’20: $30MQ1 ’21: $45MQ1 ’21Q2 ’21: $50MQ3 ’21: $51MQ3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 75.6%Other: 22.1%ETP: 2.3%
  • Common Stock · 75.6% · $22M
  • Other · 22.1% · $7M
  • ETP · 2.3% · $687,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GAMIDA CELL LTDNEW+50.0K50.0K+$420,000$420,000
AMARIN CORP PLCADDED+200.0K300.0K+$1M$1M
PROSHARES TRSOLD OUT−350.0K0−$3M$0
PROSHARES TR IIADDED+25.0K50.0K+$177,000$687,000
JAZZJAZZ PHARMACEUTICALS PLCTRIMMED−15.0K10.0K−$2M$2M
VYNE THERAPEUTICS INCADDED+200.0K2.00M+$172,000$3M
ABBVABBVIE INCHELD+035.0K+$684,000$4M
ANTARES PHARMA INCHELD+0500.0K+$645,000$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ABBVABBVIE INChistory →COM12.63%$4M35.0K
2GLAXOSMITHKLINE PLCSPONSORED ADR12.40%$4M100.0K
3VYNE THERAPEUTICS INCCOM NEW10.65%$3M2.00M
4GILDGILEAD SCIENCES INChistory →COM9.81%$3M50.0K
5TYME TECHNOLOGIES INCCOM8.94%$3M2.17M
6ANTARES PHARMA INCCOM6.72%$2M500.0K
7MCKMCKESSON CORPhistory →COM5.86%$2M10.0K
8JAZZJAZZ PHARMACEUTICALS PLChistory →SHS USD5.56%$2M10.0K
9CAHCARDINAL HEALTH INChistory →COM4.51%$1M25.0K
10CLOVIS ONCOLOGY INCCOM4.04%$1M250.0K
11GREENLANE HLDGS INCCL A3.34%$990,000250.0K
12ADAMAS PHARMACEUTICALS INCCOM1.46%$433,000100.0K
13GAMIDA CELL LTDSHS1.42%$420,00050.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$51M25Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$50M23Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$45M22May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$30M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$30M18Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$39M19Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$59M26May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$34M16Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$55M22Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$53M19Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$26M10May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.